| Name | Title | Contact Details |
|---|
Cedars-Sinai is a non-profit, academic, community-centric, Level 1 Trauma Center in Los Angeles, California. Recognized internationally, Cedars-Sinai brings together top healthcare professionals collaborating to provide exceptional patient care. A combination of patient satisfaction scores, clinical performance initiatives, excellent medical outcomes, national designations and awards and ongoing research and academic programs have earned Cedars-Sinai a top spot on the Honor Roll in the 2014-15 issue of America`s Best Hospitals by U.S. News and World Report. Out of nearly 5,000 hospitals surveyed for the annual rankings, Cedars-Sinai is among just 17 hospitals nationwide to earn the magazine’s Honor Roll designation. To be named to the Honor Roll, a hospital must be rated among the nation’s top 50 programs in at least six specialties. Cedars-Sinai was ranked in 12 categories, including: Cancer; Cardiology and Heart Surgery; Diabetes and Endocrinology; Ear, Nose and Throat; Gastroenterology and GI Surgery; Geriatrics; Gynecology; Nephrology, Neurology and Neurosurgery; Orthopedics; Pulmonology; and Urology. Cedars-Sinai has also received its fourth consecutive Magnet® recognition for nursing excellence from the American Nurses Credentialing Center (ANCC), becoming the hospital with the longest-running Magnet designation in California. Nationwide, only about 5% of hospitals have earned the four-year Magnet designation. Cedars-Sinai was the first Southern California hospital to earn the Magnet honor in 2000, and one of only six hospitals to receive this designation three times. Studies show that Magnet hospitals tend to have lower mortality and infection rates, as well as higher patient satisfaction and nurse staffing levels.
I Know Cpr is a Marysville, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.
We are a human-centered robotics company. Our mission is to make technical advances towards robots and humans working together side by side, with an emphasis on human-centric design. Diligent Robotics is developing a suite of artificial intelligence that enables robots to collaborate with and adapt to humans in everyday environments.
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.